• Most Popular
  • Most Shared

Genmab jumps 32 pct on successful drug study

COPENHAGEN
Fri Aug 1, 2008 3:13am EDT

Stocks

   

COPENHAGEN (Reuters) - Shares in Danish biotech firm Genmab (GEN.CO) rose 32 percent in early trade on Friday after an experimental treatment for leukemia it developed with GlaxoSmithKline (GSK.L) proved effective in a pivotal trial.

Asian Markets

The companies said late on Thursday the antibody drug met its goal in the study of difficult-to-treat patients with chronic lymphocytic leukemia (LCC), producing a response rate well in excess of the 25 percent minimum needed.

By 3:07 a.m. EDT, Genmab traded up 31 percent at 336 crowns.

(Reporting by Gelu Sulugiuc; Editing by Paul Bolding)
Asian Markets


More from Reuters

Photo

Employers see uptick in hiring in 2010

NEW YORK (Reuters) - U.S. employers expect to hire more new workers in 2010 than they did in 2009, a sign the U.S. recession may be easing its grip, research showed on Tuesday.

» More Top News
An employee swipes a customer's credit card through the card reader at a restaurant in Tokyo February 19, 2005.REUTERS/Issei Kato

Taking a swipe at credit cards

New legislation meant to protect consumers could be a "game changer" for the industry -- and not in a good way.  Full Article 

Economy
A young Kamchatka brown bear plays in its enclosure at the 'Tierpark Hagenbeck' zoo in Hamburg September 20, 2007. REUTERS/Christian Charisius

The return of the Russian bear

Jason Bush

As Russia's memories of crippling economic times fade, are reforms disappearing along with them?  Commentary 

Breakingviews